Apalutamide (Erleada®). HTA ID: 20010
Apalutamide is indicated for adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 26/02/2020 |
| Rapid review completed | 23/03/2020 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 24/03/2020 |
| Pre-submission consultation with Applicant | 15/06/2020 |
| Full HTA submission received from Applicant | 20/04/2021 |
| Preliminary review sent to Applicant | 01/11/2021 |
| NCPE assessment re-commenced | 26/11/2021 |
| Factual accuracy check sent to Applicant | 09/02/2022 |
| NCPE assessment re-commenced | 17/02/2022 |
| NCPE assessment completed | 03/03/2022 |
| NCPE assessment outcome | The NCPE recommends that apalutamide (Erleada®) in combination with androgen deprivation therapy be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.